CiteFacts · FDA Drug Shortages · FDA source

FDA shortage status: Meperidine Hydrochloride Injection

FDA shortage status · Source checked 2026-10-06T18:55:41+00:00

FDA source answer

FDA currently lists this ingredient in shortage.

FDA source statuses: Current. First FDA posting: 2025-05-30. Latest FDA row update: 2026-09-22.

FDA lists 6 package records, with companies: Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals USA, Inc., Hospira, Inc., Hospira, Inc., a Pfizer Company. Package NDCs: 0409-1176-30, 0409-1178-30, 0409-1181-30, 0641-6052-25, 0641-6053-25, 0641-6054-25.

FDA shortage reason: Not stated in the grouped FDA source rows.

This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.

FDA package and manufacturer records

CompanyPackage NDCPresentationFDA availability fieldFDA update
Hikma Pharmaceuticals USA, Inc.0641-6054-25Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)Available2026-09-18
Hikma Pharmaceuticals USA, Inc.0641-6052-25Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)Available2026-09-18
Hikma Pharmaceuticals USA, Inc.0641-6053-25Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)Available2026-09-18
Hospira, Inc., a Pfizer Company0409-1176-30Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)Available2026-09-22
Hospira, Inc., a Pfizer Company0409-1178-30Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)Available2026-09-22
Hospira, Inc., a Pfizer Company0409-1181-30Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)Available2026-09-22

Source facts

Grouped generic ingredient: Meperidine Hydrochloride Injection · 6 package records

Therapeutic categories: Analgesia/Addiction
Dosage forms: Injection
Routes: INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

Open FDA source data · JSON · Markdown

FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.